Immunohistochemistry revealed a significant decrease in Ki67 staining, a marker of cell proliferation, in both ELE/ENZ and DSF/ENZ combination groups compared to monotherapies (Figure 4E), indicating effective suppression of tumor cell proliferation. The gene discussed is MKI67; the disease is neoplasm.